News
Wegovy maker cuts weight-loss drug's price to $199
Digest more
Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at ...
It's plainly apparent that Novo Nordisk has had May 22 circled its calendar since February, when the FDA began the countdown ...
10d
Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.
Analysts at Citi and Bank of America (NYSE:BAC) are maintaining a cautious stance on Hims & Hers Health as competition in the GLP-1 space intensifies and growth begins to moderate.
Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo ...
Health and wellness company, which sold alternatives to weight-loss drugs like Wegovy, is now collaborating with Wegovy-maker ...
Novo Nordisk said on Tuesday it was working with telehealth firms Hims & Hers , Ro and LifeMD to sell Wegovy, as it looks to ...
The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last year's $0.10 EPS on $278 million in sales.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback